Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Retained Earnings (2016 - 2025)

Dare Bioscience (DARE) has disclosed Retained Earnings for 11 consecutive years, with -$187.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 10.29% year-over-year to -$187.2 million, compared with a TTM value of -$187.2 million through Sep 2025, down 10.29%, and an annual FY2024 reading of -$428809.0, down 18.82% over the prior year.
  • Retained Earnings was -$187.2 million for Q3 2025 at Dare Bioscience, down from -$402826.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at -$98229.0 in Q1 2021 and bottomed at -$187.2 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$95.4 million, with a median of -$118.1 million recorded in 2022.
  • The sharpest move saw Retained Earnings soared 99.8% in 2021, then crashed 120536.47% in 2022.
  • Year by year, Retained Earnings stood at -$110.1 million in 2021, then fell by 28.1% to -$141.1 million in 2022, then soared by 99.74% to -$360896.0 in 2023, then fell by 18.82% to -$428809.0 in 2024, then tumbled by 43566.8% to -$187.2 million in 2025.
  • Business Quant data shows Retained Earnings for DARE at -$187.2 million in Q3 2025, -$402826.0 in Q2 2025, and -$179.7 million in Q1 2025.